New bispecific antibody D3L-002 enters first human trial for Hard-to-Treat cancers
NCT ID NCT07667842
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 1 trial tests D3L-002, a new drug that targets two immune checkpoints (TIGIT and PVRIG) to help the immune system fight cancer. It is for 24 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- D3L-002 (a bispecific antibody that targets two immune checkpoints, TIGIT and PVRIG)
- What this could lead to
- If this early trial shows safety and hints of tumor shrinkage, it could lead to a new treatment option for people with advanced solid tumors that have stopped responding to other therapies.
- What could go wrong
- This is a very early Phase 1 study with only 24 people, focused on safety and dosing. It is too soon to know if D3L-002 will work against cancer, and it may cause side effects or show no benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a protein calm the immune System's overreaction to cancer treatment?
- Can a new drug shrink Hard-to-Treat tumors?
- Can a Custom-Made immune cell vaccine turn the tide against solid tumors?